Information updates

Supply of EpiPen® Jr with 30 November 2017 expiry during temporary shortage

November 8, 2017

Mylan Australia is experiencing a temporary shortage of EpiPen® Jr 150mcg adrenaline (epinephrine) autoinjectors. This supply disruption is due to an unforeseen delay in supply from the overseas manufacturer. In the meantime, to minimise the impact on patient care, Mylan has put a process in place to ensure those most at-risk have access to emergency supply.

Mylan Australia wishes to advise that they will be supplying eligible patients with an EpiPen® Jr, expiring on 30 November 2017, at no charge.

Requests will only be accepted for patients requiring an EpiPen® Jr before the end of the month and who do not have access to another in-date EpiPen® Jr. This is a temporary solution until regular supply returns to the Australian market.

Patients can obtain supply by contacting their pharmacy. Pharmacists should then contact the Mylan Customer Support team on 1800 274 276 to request an EpiPen® Jr (expiring on 30 November 2017) that will be supplied to the pharmacy and patient at no charge.

Patients will need to return to their pharmacy with their prescription to replace the EpiPen® Jr at the end of November. Mylan expects stock to be available mid-to-late November 2017.

ASCIA recommends EpiPen® Jr 150mcg for patients weighing between 10-20kgs and EpiPen® 300mcg for patients 20kgs and over. 

Pharmacists with any issues regarding supply of EpiPen® Jr or EpiPen® should contact the Mylan Customer Support team on 1800 274 276. 

Please note that New Zealand is not affected by this temporary shortage. 

For further information about anaphylaxis go to

Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:


ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.



This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.